NYSE:CRY - Cryolife Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$27.03 +1.18 (+4.56 %)
(As of 02/15/2019 04:00 PM ET)
Previous Close$25.85
Today's Range$24.85 - $27.19
52-Week Range$17.70 - $36.05
Volume696,600 shs
Average Volume157,041 shs
Market Capitalization$999.25 million
P/E Ratio103.96
Dividend YieldN/A
Beta0.47
CryoLife, Inc. is a medical devices company, which engages in the processing and distribution of implantable human tissues for use in cardiac and vascular surgeries. It operates through the Medical Devices and Preservation Services segments. The Medical Devices segment includes BioGlue; BioFoam; On-X products; CardioGenesis cardiac laser therapy; PerClot; PhotoFix, Hemodialysis Reliable Outflow Graft; and ProCol Vascular Bioprosthesis. The Preservation Services segment offers preservation of cardiac and vascular tissues. The company was founded on January 19, 1984 and is headquartered in Kennesaw, GA.

Receive CRY News and Ratings via Email

Sign-up to receive the latest news and ratings for CRY and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
CUSIP22890310
Phone770-419-3355

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$262.84 million
Cash Flow$0.6298 per share
Book Value$8.28 per share

Profitability

Net Income$3.70 million

Miscellaneous

Employees1,000
Market Cap$999.25 million
OptionableOptionable

Cryolife (NYSE:CRY) Frequently Asked Questions

What is Cryolife's stock symbol?

Cryolife trades on the New York Stock Exchange (NYSE) under the ticker symbol "CRY."

How were Cryolife's earnings last quarter?

Cryolife Inc (NYSE:CRY) issued its quarterly earnings data on Wednesday, February, 13th. The medical equipment provider reported $0.05 EPS for the quarter, missing the Thomson Reuters' consensus estimate of $0.12 by $0.07. The medical equipment provider had revenue of $67.80 million for the quarter, compared to analysts' expectations of $67.10 million. Cryolife had a positive return on equity of 3.49% and a negative net margin of 1.45%. View Cryolife's Earnings History.

When is Cryolife's next earnings date?

Cryolife is scheduled to release their next quarterly earnings announcement on Wednesday, May 1st 2019. View Earnings Estimates for Cryolife.

What guidance has Cryolife issued on next quarter's earnings?

Cryolife updated its FY19 earnings guidance on Thursday, February, 14th. The company provided earnings per share (EPS) guidance of $0.28-0.32 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.45. The company issued revenue guidance of $280-284 million, compared to the consensus revenue estimate of $282.04 million.

What price target have analysts set for CRY?

2 equities research analysts have issued twelve-month target prices for Cryolife's stock. Their forecasts range from $32.00 to $36.00. On average, they anticipate Cryolife's stock price to reach $34.00 in the next year. This suggests a possible upside of 25.8% from the stock's current price. View Analyst Price Targets for Cryolife.

What is the consensus analysts' recommendation for Cryolife?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cryolife in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cryolife.

What are Wall Street analysts saying about Cryolife stock?

Here are some recent quotes from research analysts about Cryolife stock:
  • 1. According to Zacks Investment Research, "CryoLife, Inc. is a leader in medical device manufacturing and distribution and in the processing and distribution of implantable living human tissues for use in cardiac and vascular surgeries. It operates throughout the U.S. and internationally. CryoLife manufactures and distributes BioGlue Surgical Adhesive, an FDA-approved adjunct to sutures and staples for use in adult patients in open surgical repair of large vessels. BioGlue is also CE marked in Europe for use in soft tissue repair and has received additional marketing approvals in several other countries throughout the world. CryoLife's BioFoam Surgical Matrix is CE marked in Europe for use as an adjunct to hemostasis in cardiovascular surgery and on abdominal parenchymal tissues (liver and spleen) when control of bleeding by ligature or conventional methods is ineffective or impractical. CryoLife distributes PerClot, a powdered hemostat, in Europe and other select international countries. " (2/4/2019)
  • 2. Northland Securities analysts commented, "We continue to be strongly bullish on CryoLife. Our thesis is predicated on a few simple things: 1) Our belief in the New product intros over the next few years. The stock currently trades at ~4x Sales, which is a discount to the 5.2x multiple for the broader space. For sure, the volatility in CryoLife stock will not be as much as other players in the space. But this is a steady eddy story." (1/17/2019)

Has Cryolife been receiving favorable news coverage?

News headlines about CRY stock have been trending somewhat positive recently, InfoTrie Sentiment reports. The research group identifies negative and positive press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Cryolife earned a media sentiment score of 1.3 on InfoTrie's scale. They also gave news stories about the medical equipment provider a news buzz of 1.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near term.

Who are some of Cryolife's key competitors?

Who are Cryolife's key executives?

Cryolife's management team includes the folowing people:
  • James Patrick Mackin, Chairman, President & Chief Executive Officer
  • David Ashley Lee, Chief Operating & Financial Officer, Executive VP
  • Scott B. Capps, Vice President-Clinical Research
  • Jean F. Holloway, Secretary, Chief Compliance Officer & Senior VP
  • James McDermid, Chief Human Resources Officer & Senior VP

Who are Cryolife's major shareholders?

Cryolife's stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (14.97%), Dimensional Fund Advisors LP (5.22%), Macquarie Group Ltd. (4.42%), Northern Trust Corp (3.17%), Bank of New York Mellon Corp (1.19%) and Geode Capital Management LLC (0.99%). Company insiders that own Cryolife stock include Amy Horton, C Elkins Ronald, David Ashley Lee, David C Gale, Harvey Morgan, James Benson, James P Mackin, Jean F Holloway, John E Davis, Ronald D Mccall and Scott B Capps. View Institutional Ownership Trends for Cryolife.

Which institutional investors are selling Cryolife stock?

CRY stock was sold by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP, Elk Creek Partners LLC, Barclays PLC, Castleark Management LLC, Bank of New York Mellon Corp, MetLife Investment Advisors LLC, Royce & Associates LP and New York State Common Retirement Fund. Company insiders that have sold Cryolife company stock in the last year include Amy Horton, C Elkins Ronald, David Ashley Lee, Harvey Morgan, James P Mackin, Jean F Holloway, John E Davis, Ronald D Mccall and Scott B Capps. View Insider Buying and Selling for Cryolife.

Which institutional investors are buying Cryolife stock?

CRY stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., First Trust Advisors LP, Monarch Partners Asset Management LLC, Dupont Capital Management Corp, Geode Capital Management LLC, Rhumbline Advisers, Oberweis Asset Management Inc. and Gotham Asset Management LLC. View Insider Buying and Selling for Cryolife.

How do I buy shares of Cryolife?

Shares of CRY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Cryolife's stock price today?

One share of CRY stock can currently be purchased for approximately $27.03.

How big of a company is Cryolife?

Cryolife has a market capitalization of $999.25 million and generates $262.84 million in revenue each year. The medical equipment provider earns $3.70 million in net income (profit) each year or $0.26 on an earnings per share basis. Cryolife employs 1,000 workers across the globe.

What is Cryolife's official website?

The official website for Cryolife is http://www.cryolife.com.

How can I contact Cryolife?

Cryolife's mailing address is 1655 Roberts Boulevard N.W, Kennesaw GA, 30144. The medical equipment provider can be reached via phone at 770-419-3355 or via email at [email protected]


MarketBeat Community Rating for Cryolife (NYSE CRY)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  270 (Vote Outperform)
Underperform Votes:  196 (Vote Underperform)
Total Votes:  466
MarketBeat's community ratings are surveys of what our community members think about Cryolife and other stocks. Vote "Outperform" if you believe CRY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CRY will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/15/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel